147 related articles for article (PubMed ID: 36042124)
1. Management of Clinical T2N0 Esophageal and Gastroesophageal Junction Adenocarcinoma: What Is the Optimal Treatment?
Perez Holguin RA; Olecki EJ; Stahl KA; Wong WG; Vining CC; Dixon MEB; Peng JS
J Gastrointest Surg; 2022 Oct; 26(10):2050-2060. PubMed ID: 36042124
[TBL] [Abstract][Full Text] [Related]
2. Comparative effectiveness of upfront esophagectomy versus induction chemoradiation in clinical stage T2N0 esophageal cancer: A decision analysis.
Semenkovich TR; Panni RZ; Hudson JL; Thomas T; Elmore LC; Chang SH; Meyers BF; Kozower BD; Puri V
J Thorac Cardiovasc Surg; 2018 May; 155(5):2221-2230.e1. PubMed ID: 29428700
[TBL] [Abstract][Full Text] [Related]
3. Clinical T2N0 Esophageal Cancer: Identifying Pretreatment Characteristics Associated With Pathologic Upstaging and the Potential Role for Induction Therapy.
Samson P; Puri V; Robinson C; Lockhart C; Carpenter D; Broderick S; Kreisel D; Krupnick AS; Patterson GA; Meyers B; Crabtree T
Ann Thorac Surg; 2016 Jun; 101(6):2102-11. PubMed ID: 27083246
[TBL] [Abstract][Full Text] [Related]
4. Induction therapy does not improve survival for clinical stage T2N0 esophageal cancer.
Speicher PJ; Ganapathi AM; Englum BR; Hartwig MG; Onaitis MW; D'Amico TA; Berry MF
J Thorac Oncol; 2014 Aug; 9(8):1195-201. PubMed ID: 25157773
[TBL] [Abstract][Full Text] [Related]
5. Survival outcomes in patients with gastric and gastroesophageal junction adenocarcinomas treated with perioperative chemotherapy with or without preoperative radiotherapy.
Tian S; Jiang R; Madden NA; Ferris MJ; Buchwald ZS; Xu KM; Cardona K; Maithel SK; McDonald MW; Lin JY; Curran WJ; El-Rayes BF; Behera M; Patel PR
Cancer; 2020 Jan; 126(1):37-45. PubMed ID: 31532544
[TBL] [Abstract][Full Text] [Related]
6. Outcomes of Neoadjuvant Chemoradiation in Patients with Gastro-esophageal Junction Adenocarcinoma: a Retrospective Cohort Study in Iran.
Farhan F; Ghalehtaki R; Mahdavi-Seresht S; Meysamie A; Yamrali M; Farazmand B; Mohammadi N; Saraee E; Mir MR; Mir A; Lashkari M; Salarvand S; Esmati E; Samiei F
J Gastrointest Cancer; 2019 Dec; 50(4):907-912. PubMed ID: 30402826
[TBL] [Abstract][Full Text] [Related]
7. The Role of Continuing Perioperative Chemotherapy Post Surgery in Patients with Esophageal or Gastroesophageal Junction Adenocarcinoma: a Multicenter Cohort Study.
Papaxoinis G; Kamposioras K; Weaver JMJ; Kordatou Z; Stamatopoulou S; Germetaki T; Nasralla M; Owen-Holt V; Anthoney A; Mansoor W
J Gastrointest Surg; 2019 Sep; 23(9):1729-1741. PubMed ID: 30671799
[TBL] [Abstract][Full Text] [Related]
8. Survival in Patients With Esophageal Adenocarcinoma Undergoing Trimodality Therapy Is Independent of Regional Lymph Node Location.
Sepesi B; Schmidt HE; Lada M; Correa AM; Walsh GL; Mehran RJ; Rice DC; Roth JA; Vaporciyan AA; Ajani JA; Watson TJ; Swisher SG; Low DE; Hofstetter WL
Ann Thorac Surg; 2016 Mar; 101(3):1075-80; Discussion 1080-1. PubMed ID: 26680311
[TBL] [Abstract][Full Text] [Related]
9. Prognosis after neoadjuvant chemoradiation or chemotherapy for locally advanced gastro-oesophageal junctional adenocarcinoma.
Vos EL; Carr RA; Hsu M; Nakauchi M; Nobel T; Russo A; Barbetta A; Tan KS; Tang L; Ilson D; Ku GY; Wu AJ; Janjigian YY; Yoon SS; Bains MS; Jones DR; Coit D; Molena D; Strong VE
Br J Surg; 2021 Nov; 108(11):1332-1340. PubMed ID: 34476473
[TBL] [Abstract][Full Text] [Related]
10. Tumor stage after neoadjuvant chemotherapy determines survival after surgery for adenocarcinoma of the esophagus and esophagogastric junction.
Davies AR; Gossage JA; Zylstra J; Mattsson F; Lagergren J; Maisey N; Smyth EC; Cunningham D; Allum WH; Mason RC
J Clin Oncol; 2014 Sep; 32(27):2983-90. PubMed ID: 25071104
[TBL] [Abstract][Full Text] [Related]
11. Neoadjuvant therapy or upfront surgery? A systematic review and meta-analysis of T2N0 esophageal cancer treatment options.
Mota FC; Cecconello I; Takeda FR; Tustumi F; Sallum RAA; Bernardo WM
Int J Surg; 2018 Jun; 54(Pt A):176-181. PubMed ID: 29730075
[TBL] [Abstract][Full Text] [Related]
12. Esophagectomy vs Gastrectomy for Early Stage Adenocarcinoma of the Gastroesophageal Junction: What is the Optimal Oncologic Surgical Treatment?
Holguin RAP; Wong WG; Shen C; Go PH; Reed MF; Taylor MD
Semin Thorac Cardiovasc Surg; 2023 Winter; 35(4):807-819. PubMed ID: 35926763
[TBL] [Abstract][Full Text] [Related]
13. Long-Term Survival in Patients with Gastroesophageal Junction Cancer Treated with Preoperative Therapy: Do Thoracic and Abdominal Approaches Differ?
Kneuertz PJ; Hofstetter WL; Chiang YJ; Das P; Blum M; Elimova E; Mansfield P; Ajani J; Badgwell B
Ann Surg Oncol; 2016 Feb; 23(2):626-32. PubMed ID: 26564243
[TBL] [Abstract][Full Text] [Related]
14. Neoadjuvant Therapy Vs Upfront Surgery for Clinical T2N0 Esophageal Cancer: A Systematic Review.
Kidane B; Korst RJ; Weksler B; Farrell A; Darling GE; Martin LW; Reddy R; Sarkaria IS
Ann Thorac Surg; 2019 Sep; 108(3):935-944. PubMed ID: 31077657
[TBL] [Abstract][Full Text] [Related]
15. A bridging stent to surgery in patients with esophageal and gastroesophageal junction cancer has a dramatic negative impact on patient survival: A retrospective cohort study through data acquired from a prospectively maintained national database.
Kjaer DW; Nassar M; Jensen LS; Svendsen LB; Mortensen FV
Dis Esophagus; 2017 Feb; 30(3):1-7. PubMed ID: 27001181
[TBL] [Abstract][Full Text] [Related]
16. Contemporary outcomes of esophageal and gastroesophageal junction neuroendocrine tumors.
Poston LM; Gupta S; Alvarado CE; Sinopoli J; Vargas LT; Linden PA; Towe CW
Dis Esophagus; 2023 Jul; 36(8):. PubMed ID: 36688874
[TBL] [Abstract][Full Text] [Related]
17. Endoscopic ultrasound for esophageal and gastroesophageal junction cancer: Impact of increased use of primary neoadjuvant therapy on preoperative locoregional staging accuracy.
DeWitt J; Kesler K; Brooks JA; LeBlanc J; McHenry L; McGreevy K; Sherman S
Dis Esophagus; 2005; 18(1):21-7. PubMed ID: 15773837
[TBL] [Abstract][Full Text] [Related]
18. Adenocarcinoma of the gastroesophageal junction: influence of esophageal resection margin and operative approach on outcome.
Barbour AP; Rizk NP; Gonen M; Tang L; Bains MS; Rusch VW; Coit DG; Brennan MF
Ann Surg; 2007 Jul; 246(1):1-8. PubMed ID: 17592282
[TBL] [Abstract][Full Text] [Related]
19. No Survival Difference with Neoadjuvant Chemoradiotherapy Compared with Chemotherapy in Resectable Esophageal and Gastroesophageal Junction Adenocarcinoma: Results from the National Cancer Data Base.
Al-Sukhni E; Gabriel E; Attwood K; Kukar M; Nurkin SJ; Hochwald SN
J Am Coll Surg; 2016 Dec; 223(6):784-792.e1. PubMed ID: 27641320
[TBL] [Abstract][Full Text] [Related]
20. Age-dependent benefit of neoadjuvant treatment in adenocarcinoma of the esophagus and gastroesophageal junction: a multicenter retrospective observational study of young versus old patients.
Rompen IF; Crnovrsanin N; Nienhüser H; Neuschütz K; Fourie L; Sisic L; Müller-Stich BP; Billeter AT
Int J Surg; 2023 Dec; 109(12):3804-3814. PubMed ID: 37720939
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
